Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
284.059720369
InChI
InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)
InChI Key
InChIKey=OOUGLTULBSNHNF-UHFFFAOYSA-N
IUPAC Name
3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
Traditional IUPAC Name
ataluren
SMILES
OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F
pKa (strongest acidic)
3.9
pKa (Strongest Basic)
-1.6
Refractivity
94.66 m3·mol-1
Cơ Chế Tác Dụng :
PTC124 is a novel, orally administered drug that targets nonsense mutations and is being investigated initially as a treatment for Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF), with the potential to treat a number of other genetic disorders caused by nonsense mutations.
PTC124 allowed the cellular machinery to bypass the nonsense mutation, continue the translation process, and thereby restore the production of a full-length, functional protein.
The research on the effects of PTC124 on the translation and stability of nonsense-containing mRNA in vitor show that PTC124 promoted readthrough at each of the nonsense codons, showing maximal activity with UGA, while having no effect on mRNA levels. Unlike the stable cell line assays, PTC124 did not discriminate significantly between the UAG and UAA mRNAs. PTC124 was a more potent nonsense-suppressing agent than gentamicin, and exhibited 4- to 15-fold stimulation of in vitro readthrough relative to the controls at levels similar to those in the stable cell reporter assays. These results indicate that PTC124 modulates termination efficiency at premature nonsense codons.
Dược Động Học :
▧ Half Life :
3-6 hours
Chỉ Định :
Investigated for use/treatment in cystic fibrosis and muscular dystrophy.